All In Biotech

Drug Trial Radar · NCT07946757

Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B

A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Feb 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Beijing Ditan Hospital
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.

Conditions

  • Chronic Hepaititis B

Interventions

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

  • PegIFNα-2b InjectionDrug

    Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol

  • Tenofovir Alafenamide Fumarate(TAF)Drug

    Once daily, orally, until the end of the trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)Time frame: throughout the full study period,an average of 38 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.